Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR-HCM
NCT06580717Phase 4Recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in hypertrophic cardiomyopathy (HCM), sponsored by Yonsei University. Started Oct 2024; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06580717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580717.